Dogwood Therapeutics, Stock Performance
| DWTX Stock | 6.33 0.50 7.32% |
Dogwood Therapeutics, holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 9.48, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Dogwood Therapeutics, will likely underperform. Use Dogwood Therapeutics, downside variance, and the relationship between the total risk alpha and daily balance of power , to analyze future returns on Dogwood Therapeutics,.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Dogwood Therapeutics, are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Dogwood Therapeutics, showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (7.32) | Five Day Return 11.64 | Year To Date Return 152.19 | Ten Year Return (98.48) | All Time Return (98.48) |
Last Split Factor 1:25 | Last Split Date 2024-10-09 |
1 | Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial | 01/21/2025 |
2 | Insider Trading | 01/28/2025 |
3 | Virios Therapeutics vs. Q BioMed Head to Head Comparison | 02/19/2025 |
4 | Dogwood Therapeutics, Inc. Announces Conversion of Existing 19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward | 03/12/2025 |
5 | Dogwood Therapeutics, Inc. Announces Pricing of 4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules | 03/13/2025 |
6 | DWTX First Patient Dosed in Phase 2b Trial of Halneuron in CINP Debt Conversion Strengthens Balance Sheet | 03/18/2025 |
| Begin Period Cash Flow | 7 M |
Dogwood |
Dogwood Therapeutics, Relative Risk vs. Return Landscape
If you would invest 287.00 in Dogwood Therapeutics, on December 24, 2024 and sell it today you would earn a total of 346.00 from holding Dogwood Therapeutics, or generate 120.56% return on investment over 90 days. Dogwood Therapeutics, is currently generating 6.0397% in daily expected returns and assumes 50.9906% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Dogwood, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dogwood Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dogwood Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dogwood Therapeutics,, and traders can use it to determine the average amount a Dogwood Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1184
| Best Portfolio | Best Equity | DWTX | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 50.99 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.96 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Dogwood Therapeutics, is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dogwood Therapeutics, by adding it to a well-diversified portfolio.
Dogwood Therapeutics, Fundamentals Growth
Dogwood Stock prices reflect investors' perceptions of the future prospects and financial health of Dogwood Therapeutics,, and Dogwood Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dogwood Stock performance.
| Return On Equity | -2.0 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 6.13 M | ||||
| Shares Outstanding | 1.33 M | ||||
| Price To Book | 8.60 X | ||||
| Net Income | (5.3 M) | ||||
| Total Debt | 358.55 K | ||||
| Book Value Per Share | 0.85 X | ||||
| Cash Flow From Operations | (4.87 M) | ||||
| Earnings Per Share | (6.32) X | ||||
| Total Asset | 4.17 M | ||||
| Retained Earnings | (61.47 M) | ||||
About Dogwood Therapeutics, Performance
Evaluating Dogwood Therapeutics,'s performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Dogwood Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dogwood Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Dogwood Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about Dogwood Therapeutics, performance evaluation
Checking the ongoing alerts about Dogwood Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dogwood Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dogwood Therapeutics, is way too risky over 90 days horizon | |
| Dogwood Therapeutics, appears to be risky and price may revert if volatility continues | |
| Dogwood Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Dogwood Therapeutics, was previously known as VIRI Old and was traded on NASDAQ Exchange under the symbol VIRI. | |
| Net Loss for the year was (5.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dogwood Therapeutics, generates negative cash flow from operations | |
| About 21.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: DWTX First Patient Dosed in Phase 2b Trial of Halneuron in CINP Debt Conversion Strengthens Balance Sheet |
- Analyzing Dogwood Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dogwood Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Dogwood Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dogwood Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dogwood Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dogwood Therapeutics,'s stock. These opinions can provide insight into Dogwood Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Dogwood Stock Analysis
When running Dogwood Therapeutics,'s price analysis, check to measure Dogwood Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dogwood Therapeutics, is operating at the current time. Most of Dogwood Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Dogwood Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dogwood Therapeutics,'s price. Additionally, you may evaluate how the addition of Dogwood Therapeutics, to your portfolios can decrease your overall portfolio volatility.